ATLASMineralys Therapeutics (MLYS) earnings date: Nov 4, 2026
Mineralys Therapeutics (MLYS) reports earnings for the quarter ended Sep 30, 2026 on Wed, Nov 4, 2026, after the close. Analysts expect EPS of -$0.53.
Source: company filings and exchange data · Updated Nov 2, 2026
ATLAS view on MLYS
| Last price | $18.18 (-14.4%) |
|---|---|
| Normal 1-day range (±1σ) | ±4.5% |
| Earnings beat history | Beat the EPS estimate in 0 of the last 3 reports |
These figures come from the same calibrated model and valuation as the Mineralys Therapeutics stock page. They describe an ordinary period, not the earnings reaction itself, which is usually wider and can go either way.
Mineralys Therapeutics reports on Nov 4, 2026. One email the day before, with ATLAS’s read on Mineralys Therapeutics. You can switch it off at any time.
Alert me before MLYS reportsFree to start. Creating an account takes under a minute.
MLYS earnings at a glance
| Next report (confirmed) | Wed, Nov 4, 2026 |
|---|---|
| Time | After the close |
| Period | Quarter ended Sep 30, 2026 |
| EPS estimate | -$0.53 |
| Last report | Aug 11, 2026 · Miss |
| Beat rate (last 3 reports) | 0 of 3 (0%) |
| Average EPS surprise | -147.7% |
| Average move around a report | ±1.4% (last 3) |
| Sector | Healthcare · Biotechnology |
Mineralys Therapeutics earnings history: last 3 reports
Mineralys Therapeutics last reported on Aug 11, 2026: EPS of -$2.85 against an estimate of -$0.53 (-437.7% surprise), a miss.
| Report date | EPS est. | EPS actual | Surprise | Result | Move* |
|---|---|---|---|---|---|
| Aug 11, 2026 | -$0.53 | -$2.85 | -437.7% | Miss | -1.2% |
| Jun 17, 2026 | $3.12 | $3.16 | +1.3% | In line | +2.7% |
| May 6, 2026 | -$0.44 | -$0.47 | -6.8% | Miss | +0.2% |
*Move: change in the closing price from the last close before the report day to the close the day after it, so it captures the reaction whether the company reported before the open or after the close.
Get the full ATLAS analysis for MLYS
See the fair value, the probability range and the earnings history of Mineralys Therapeutics on its ATLAS page.
Mineralys Therapeutics (MLYS) stock analysisPlans from €3.99 a month.
Mineralys Therapeutics earnings: frequently asked questions
When does Mineralys Therapeutics (MLYS) report earnings?
Mineralys Therapeutics is scheduled to report on Wednesday, November 4, 2026, after the close. ATLAS only shows a confirmed date when the company or the exchange data provides one; check the investor relations page for the call details.
What is the EPS estimate for MLYS?
The consensus EPS estimate for the quarter ended Sep 30, 2026 is -$0.53 per share (USD). Estimates can change before the report.
How often does MLYS beat earnings estimates?
Of its last 3 reports with a recorded result, Mineralys Therapeutics beat the EPS estimate 0 times; the average surprise was -147.7%. Past results do not predict the next one.
How much does MLYS move around earnings?
Over its last 3 reports the stock moved an average of 1.4% (absolute, from the close before the report day to the close after it), and finished higher 2 of 3 times.
Did Mineralys Therapeutics beat earnings estimates last quarter?
Mineralys Therapeutics last reported on Aug 11, 2026: EPS of -$2.85 against an estimate of -$0.53 (-437.7% surprise), a miss.
How much does MLYS usually move in a day?
On a normal trading day the ATLAS model puts MLYS’s one-day range at about ±4.5%, with a 49% chance of closing higher. This is not an options-implied earnings move; earnings days are usually wider.
Also reporting on Wed, Nov 4, 2026
Educational information, not investment advice. Disclaimer